Ömercan Topaloğlu

Dr. Ömercan Topaloğlu

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2022 in Clinical Endocrinology
Verified
Journal Article
Closed access
Dilek Gogas YavuzDilek Gogas Yavuz
Dilek Gogas Yavuz
CYCeyda D. Yazan
Ceyda D. Yazan
ZHZeliha Hekimsoy
Zeliha Hekimsoy
KAKadriye Aydin
Kadriye Aydin
NGNaile Gokkaya
Naile Gokkaya
EBEvin Bozkur
Evin Bozkur

25 April 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ABAdnan Batman
Adnan Batman
DYDilek Yazıcı
Dilek Yazıcı
ODOğuz Dikbaş
Oğuz Dikbaş
KAKemal Ağbaht
Kemal Ağbaht
ESEmre Sedar Saygılı
Emre Sedar Saygılı
MSMustafa - Sahin
Mustafa - Sahin
Context: The aims of the study are to compare characteristics of subacute thyroiditis (SAT) related to different etiologies, and to identify predictors of recurrence of SAT and incident hypothyroidism. Methods: This nationwide, multicenter, retrospective cohort study included 53 endocrinology centers in Turkey. The study participants were divided into either COVID-19–related SAT (Cov-SAT), SARS-CoV-2 vaccine–related SAT (Vac-SAT), or control SAT (Cont-SAT) groups. Results: Of the 811 patients, 258 (31.8%) were included in the Vac-SAT group, 98 (12.1%) in the Cov-SAT group, and 455 (56.1%) in the Cont-SAT group. No difference was found between the groups with regard to laboratory and imaging findings. SAT etiology was not an independent predictor of recurrence or hypothyroidism. In the entire cohort, steroid therapy requirement and younger age were statistically significant predictors for SAT recurrence. C-reactive protein measured during SAT onset, female sex, absence of antithyroid peroxidase (TPO) positivity, and absence of steroid therapy were statistically significant predictors of incident (early) hypothyroidism, irrespective of SAT etiology. On the other hand, probable predictors of established hypothyroidism differed from that of incident hypothyroidism. Conclusion: Since there is no difference in terms of follow-up parameters and outcomes, COVID-19– and SARS-CoV-2 vaccine–related SAT can be treated and followed up like classic SATs. Recurrence was determined by younger age and steroid therapy requirement. Steroid therapy independently predicts incident hypothyroidism that may sometimes be transient in overall SAT and is also associated with a lower risk of established hypothyroidism.

27 August 2021 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
ASAlev Selek
Alev Selek
EGEmre Gezer
Emre Gezer
EAEda Altun
Eda Altun
MSMehmet Sözen
Mehmet Sözen
ÖTÖmercan Topaloğlu
Ömercan Topaloğlu
DTDilek Guven Taymez
Dilek Guven Taymez

1 May 2022 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
ÖTÖmercan Topaloğlu
Ömercan Topaloğlu
STSakin Tekin
Sakin Tekin
STSeda Nur Topaloğlu
Seda Nur Topaloğlu
TBTaner Bayraktaroglu
Taner Bayraktaroglu
Subacute thyroiditis (SAT) developed after SARS-CoV-2 vaccines has been less studied. We aimed to compare classical SAT and SAT developed after SARS-CoV-2 vaccines in the context of clinical aspects. Adults with SAT detected in 90 days of COVID-19 vaccination (CoronaVac or Pfizer/BioNTech) were grouped as Vac-SAT. Those with a history of SARS-CoV-2 or upper respiratory tract infection in 6 months before the vaccination, or vaccination with another antiviral vaccine after COVID-19 vaccination were excluded. Those with SAT detected before COVID-19 pandemic were grouped as Classical-SAT. Of total (n=85), female/male (54/31) ratio and age [43 (23–65)] were similar in Vac-SAT (n=23) and Classical-SAT (n=62). Duration between vaccine and SAT was 45 (7–90) days, and similar in CoronaVac-SAT (n=5) and BioNTech-SAT (n=18). SAT-duration was 28 (10–150) days, and higher in Vac-SAT than in Classical-SAT (p=0.023). SAT was developed after the 1st dose vaccine in minority in CoronaVac-SAT (n=2) and BioNTech-SAT (n=3) (p=0.263). Previous LT4 use, and TSH elevation after resolution were more frequent in Vac-SAT than in Classical-SAT (p=0.027 and p=0.041). We included a considerable number of patients with SAT occurred after COVID-19 vaccines. We cannot provide clear evidence regarding the association of COVID-19 vaccines with SAT. SAT associated with CoronaVac or BioNTech seems unlikely to be occurred after the 1st dose, and to have a longer duration, more likely to be associated with previous LT4 use and lead TSH elevation after resolution than Classical-SAT. TSH should be followed-up after the resolution of SAT detected after COVID-19 vaccination.

11 May 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BEBahri Evren
Bahri Evren
SYSami Yılmaz
Sami Yılmaz
NKNeşe Karadağ
Neşe Karadağ
ASAyşe Çıkım Sertkaya
Ayşe Çıkım Sertkaya
ÖTÖmercan Topaloğlu
Ömercan Topaloğlu
FKFaruk Kılınç
Faruk Kılınç
Malignant thyroid lesions are the most common malignancy of the endocrine glands with increasing rates in the last two decades. Papillary thyroid cancer is the most common thyroid malignancy. In our study, we aimed to quantitatively evaluate the levels of DNA repair proteins MSH2, MLH1, MGMT, which are representative blocks of patients diagnosed with papillary carcinoma, chronic thyroiditis, or colloidal goiter. Total or subtotal thyroidectomy material of 90 patients diagnosed with papillary carcinoma, nodular colloidal goiter, or chronic thyroiditis between 2009 and 2012 were retrospectively evaluated. Tissue samples obtained from paraffin blocks were stained with MGMT, MSH2, MLH1 proteins and their immunohistochemistry was evaluated. Prepared sections were examined qualitatively by an impartial pathologist and a clinician, taking into account the staining method under the trinocular light microscope. Although there was no statistically significant difference in MGMT, MSH2, MLH1, follicular cell positivity, staining intensity, and immunoreactivity values, papillary carcinoma cases showed a higher rate of follicular cell positivity, and this difference was more pronounced between papillary carcinoma and colloidal goiter. In the MSH2 follicular cell positivity evaluation, the difference between chronic thyroiditis and colloidal goiter was significant (p = 0.023). The difference between chronic thyroiditis and colloidal goiter was significant in the MSH2 staining intensity evaluation (p = 0.001). The difference between chronic thyroiditis and colloidal goiter was significant in MLH1 immunoreactivity evaluation (p = 0.012). Papillary carcinoma cases were demonstrated by nuclear staining only for MSH2 and MLH1 proteins as opposed to hyperplastic nodules. The higher levels of expression of DNA repair genes in malignant tumors compared to benign tumors are attributed to the functional activation of DNA repair genes. Further studies are needed for DNA repair proteins to be a potential test in the development and progression of thyroid cancer.

17 May 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
ÖTÖmercan Topaloğlu
Ömercan Topaloğlu
AYArzu Yavuz
Arzu Yavuz
AAAhsen Banu Tiryaki Aylıkcı
Ahsen Banu Tiryaki Aylıkcı
Purpose Adherence to levothyroxine (LT4) and attaining thyroid‐stimulating hormone (TSH) goal in pregnancy has not been well‐defined yet. We aimed to investigate adherence to LT4, success to reach TSH goal, and association between them in pregnant women with primary hypothyroidism. Materials and Methods Eight‐item Morisky Medication Adherence Scale (MMAS‐8) was applied in third trimester in pregnant women with primary hypothyroidism (Hashimoto's thyroiditis, surgical hypothyroidism or iodine deficiency) whom LT4 was given for at least 3 months. Those with chronic illness or thyroid cancer were excluded. We grouped the patients according to MMAS‐8 score (<6, low adherence vs ≥6, medium/high adherence), and TSH measurement in third trimester (in‐range vs out‐of‐range). Results Of total (n = 85), 57.64% (n = 49) had medium/high adherence to LT4, and 41.17% (n = 35) out‐of‐range TSH, but no association was found among them (P = .937). LT4 initiation in pregestational period, surgical hypothyroidism, high LT4 dose in second/third trimester and alternate‐day dosing were associated with medium/high adherence. Age, number of visits, and less time between ingestion of LT4 and breakfast were associated with medium/high adherence. LT4 dose in second trimester and dose increment at the beginning of pregnancy were positively associated with in‐range TSH. Conclusion Non‐adherence and treatment failure are frequent in LT4‐treated pregnant women. Adherence seems not to be associated with treatment success. Regular follow‐up may improve adherence. Our study is the first to analyse both treatment success and adherence to LT4 in pregnancy.